The Joint Corp. · NASDAQ:JYNT
The Joint — Q4 2024 Earnings Presentation
29 slides from The Joint's earnings presentation, Mar 13, 2025
Slide 1: Q4 2024 Financial Results
Q4 2024 Financial Results As of December 31, 2024, reported March 13, 2025 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 1
Slide 2: Safe Harbor Statements
Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words such as "may," "might," " will," "expect,” "anticipate,'' "'believe,“ "could," " intend," "plan," "estimate," "should,"
Slide 3: Sanjiv Razdan, CEO, President and Director
Sanjiv Razdan CEO, President and Director NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 3
Slide 4: First 100 Days: Observations, Strategy and 2025 Plan to Win
First 100 Days: Observations, Strategy and 2025 Plan to Win NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 4
Slide 5: Our mission is to improve quality of life through routine and affordable chiropractic care
Our mission is to improve quality of life through routine and affordable chiropractic care. Our vision is to build America’s most accessible health and wellness services company. NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 5
Slide 6: Q4 2024 system-wide sales, comp sales and revenue growth
9% 6% 14% Q4 2024 Q4 2024 Q4 2024 system-wide sales1 comp sales2 revenue up from 8% in up from 4% in from continuing Q3 2024 Q3 2024 operations up 10% in Q3 2024 1 System-wide sales include revenues at all clinics, whether operated or managed by is important the company or by franchisees. While fran
Slide 7: Multi-year, Phased Approach
Multi-year, Phased Approach 2.0 3.0 Strengthen Core Capture New Revenue & Become through Additional Pure Play Franchisor Channels & Markets NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 7
Slide 8: Strengthen Clinic Economics
Excel in Patient Build People Experience Capability & Culture Strengthen Clinic OUR Turbo Economics PATIENTS Charge Sales & Profits Innovate & & Reignite Broaden Relevance Growth Rapidly Grow Clinic Network 8 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved.
Slide 9: Refranchising: Becoming a Pure Play Franchisor
Refranchising: Becoming a Pure Play Franchisor Vast Majority of Clinics in Final Stages of Letters of Intent Negotiations • Marketing in 5 geographical regions: Desert Region, SoCal, NorCal, Southeast & Kansas City Goal: To Enhance Profitability Profile • Generating capital • Increasing franchise ro
Slide 10: Drive Revenue Growth
Drive Revenue Growth • Initiate Dynamic Revenue Management • Strengthen Digital Marketing and Promotional Calendar • Upgrade Patient-facing Technology NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 10
Slide 11: Jake Singleton, Chief Financial Officer
Jake Singleton Chief Financial Officer NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 11
Slide 12: Strong Operational KPIs
Strong Operational KPIs 14.7M 1.9M 957K 36% 85% adjustments unique patients new patients of new patients were system-wide gross sales in 2024 treated in 2024 in 2024 new to chiropractic from monthly in 2024 1 memberships in 2024 Up from 13.6M in 2023 Up from 1.7M in 2023 Compared to 932K in 2023 ~34
Slide 13: Increasing Franchised Clinics to 87% Total Count
Increasing Franchised Clinics to 87% Total Count TOTAL CLINICS OPEN Franchised Company-owned and managed 967 935 125 838 135 126 706 96 579 513 64 442 60 399 48 842 370 47 800 312 61 712 47 610 246 515 4 453 394 352 309 242 265 175 82 12 26 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Slide 14: Q4 2024 Continuing Operations as of Dec. 31, 2024
Q4 2024 Continuing Operations as of Dec. 31, 2024 $ in M 1 3 mo.s 12/31/24 3 mo.s 12/31/23 Differences Revenue $14.4 $12.7 $1.7 14% Cost of revenue 3.2 2.8 0.3 12% Sales and marketing 2.7 1.7 1.0 64% Depreciation and amortization 0.3 0.3 0.0 5% G&A 7.2 6.9 0.3 5% Operating income / (loss) 0.9 1.0 (0
Slide 15: Strong Liquidity
Strong Liquidity $ in Ms 12/31/24 12/31/23 Unrestricted cash $25.1 $18.2 Restricted cash $0.9 $1.1 Available JP Morgan Chase LOC1 $20.0 $18.0 Federal tax return net operating loss carryforward was $9.1M at Dec. 31, 2024 Cash flow for the year end Dec. 31, 2024: • $9.4M from operations • $554k from t
Slide 16: 2024 Continuing Operations as of Dec. 31, 2024
2024 Continuing Operations as of Dec. 31, 2024 $ in M 1 12 mo.s 12/31/24 12 mo.s 12/31/23 Differences Revenue $51.9 $47.0 $4.9 10% Cost of revenue 11.5 10.5 1.0 10% Sales and marketing 10.9 8.7 2.2 26% Depreciation and amortization 1.4 1.3 0.1 7% G&A 29.8 26.2 3.6 14% Operating (loss) / income (1.8)
Slide 17: 2025 Guidance
2025 Guidance 2024 2025 Low 2025 High $ in M Actual Guidance Guidance $530.3 $550 $570 System-wide sales 1 System-wide comp sales for all clinics Mid-single digits open 13 months or more 2 4% Consolidated Adjusted EBTIDA 3 $11.4 $10.0 $11.5 New franchised clinic openings excluding the impact 57 30 4
Slide 18: Sanjiv Razdan, CEO, President and Director
Sanjiv Razdan CEO, President and Director NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 18
Slide 19: Reasons to Invest
Reasons to Join: Reasons to Invest Leading Chiropractic Care Franchise Concept New Large & Growing Market Strategic Attractive Asset-light Model Plan to Strong Recurring Revenue Strengthen Category Leader & Creator Core and Reignite Growth NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 1
Slide 20: Committed to Driving Success
Committed to Driving Success Net New System-wide Comp Adjusted Clinic Sales Sales EBITDA Openings NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 20
Slide 21: Contact details
Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com anjiv.razdan@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 https://www.facebook.com/thejointchiro https://www.facebook.com/thejointchiro @thejointchiro Jake Singleton, CFO https://twit
Slide 22: Performance Metrics and Non-GAAP Measures
Performance Metrics and Non-GAAP Measures This presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the inf
Slide 23: Annual Discontinued Operations
Annual Discontinued Operations 2024 NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 23 © 2024 The Joint Corp. All Rights Reserved.
Slide 24: Quarterly Recast Income
2024 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Total revenues $12,184,716 $12,610,036 $12,654,396 $14,447,457 $11,172,863 $11,504,267 $11,591,646 $12,708,701 Total costs of revenues 2,704,512 2,812,389 2,814,963 3,184,791 2,464,319 2,584,772 2,591,567 2,839,987 Selling and marketing expenses 2,237,583 3,440,391
Slide 25: GAAP – Non-GAAP Reconciliation Q4 2024 vs. Q4 2023 by Category
GAAP – Non-GAAP Reconciliation Q4 2024 vs. Q4 2023 by Category NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 25
Slide 26: GAAP – Non-GAAP Reconciliation 2024 vs. 2023 by Category
GAAP – Non-GAAP Reconciliation 2024 vs. 2023 by Category Year Ended December 31, 2024 2023 from from from from Continuing Discontinued Consolidated Continuing Discontinued Consolidated Operations Operations Operations Operations Operations Operations Non-GAAP Financial Data: (Loss) Income $ (1,536,9
Slide 27: GAAP – Non-GAAP Reconciliation Quarterly Continuing Operations
GAAP – Non-GAAP Reconciliation Quarterly Continuing Operations NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 27
Slide 28: GAAP – Non-GAAP Reconciliation Quarterly Discontinued Operations
GAAP – Non-GAAP Reconciliation Quarterly Discontinued Operations NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 28
Slide 29: GAAP – Non-GAAP Reconciliation Quarterly Consolidated Operations
GAAP – Non-GAAP Reconciliation Quarterly Consolidated Operations NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 29